Loading...
XNASONVO
Market cap5mUSD
Dec 26, Last price  
0.34USD
1D
-0.06%
1Q
-27.01%
Jan 2017
-89.97%
IPO
-92.99%
Name

Organovo Holdings Inc

Chart & Performance

D1W1MN
XNAS:ONVO chart
P/E
—
P/S
47.93
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.65%
Rev. gr., 5y
-48.78%
Revenues
109k
-70.54%
01,197,000379,000571,0001,483,0004,230,0004,603,0003,091,0002,196,00001,500,000370,000109,000
Net income
-15m
L-15.00%
-147,817-43,553,000-25,848,000-30,082,000-38,575,000-38,447,000-34,803,000-26,635,000-18,710,000-16,826,000-11,448,000-17,259,000-14,671,000
CFO
-15m
L+18.09%
-109,425-9,693,000-15,561,000-19,601,000-29,368,000-29,185,000-28,857,000-20,375,000-14,882,000-13,323,000-8,453,000-12,408,000-14,653,000
Earnings
Feb 06, 2025

Profile

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
URL
https://organovo.com/
IPO date
Aug 02, 2013
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
109
-70.54%
370
-75.33%
1,500
 
Cost of revenue
15,142
18,266
13,093
Unusual Expense (Income)
NOPBT
(15,033)
(17,896)
(11,593)
NOPBT Margin
Operating Taxes
2
2
2
Tax Rate
NOPAT
(15,035)
(17,898)
(11,595)
Net income
(14,671)
-15.00%
(17,259)
50.76%
(11,448)
-31.96%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,437
205
BB yield
-15.26%
-0.63%
Debt
Debt current
1,012
492
479
Long-term debt
2,282
3,118
3,887
Deferred revenue
Other long-term liabilities
Net debt
393
(12,540)
(24,452)
Cash flow
Cash from operating activities
(14,653)
(12,408)
(8,453)
CAPEX
(42)
(396)
(409)
Cash from investing activities
816
(966)
(409)
Cash from financing activities
1,437
205
FCF
(14,583)
(17,690)
(13,716)
Balance
Cash
2,901
16,007
28,675
Long term investments
143
143
Excess cash
2,896
16,132
28,743
Stockholders' equity
(339,659)
(324,987)
(307,730)
Invested Capital
345,160
342,121
340,122
ROIC
ROCE
EV
Common stock shares outstanding
9,145
8,713
8,704
Price
1.03
-52.97%
2.19
-41.76%
3.76
-61.00%
Market cap
9,419
-50.64%
19,082
-41.69%
32,726
-50.81%
EV
9,812
6,542
8,274
EBITDA
(14,753)
(17,603)
(11,451)
EV/EBITDA
Interest
470
8
Interest/NOPBT